Free Trial

Werewolf Therapeutics (HOWL) 10K Form and Latest SEC Filings 2026

Werewolf Therapeutics logo
$0.98 -0.01 (-0.82%)
As of 09:42 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Werewolf Therapeutics SEC Filings & Recent Activity

Werewolf Therapeutics (NASDAQ:HOWL) has submitted 367+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Werewolf Therapeutics's financial statements. The most recent filing was a Form S-4 submitted on September 22, 2026.

8-K
Werewolf Therapeutics Files Current Report on Aug. 21, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Werewolf Therapeutics Files Quarterly Report on Jul. 31, 2026

The 10-Q contains Werewolf Therapeutics's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Werewolf Therapeutics SEC Filing History

Browse Werewolf Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

Filing Date
0 Results
DateFilerForm TypeView
09/22/2026 4:04 PM
Werewolf Therapeutics (1785530) Filer
Form S-4
Registration statement under Securities Act of 1933  
09/21/2026 10:11 AM
MOLL PETER (1732748) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13G
08/21/2026 8:10 AM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/21/2026 8:12 AM
Werewolf Therapeutics (1785530) Subject
Form 425
08/20/2026 3:06 PM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2026 6:10 AM
Werewolf Therapeutics (1785530) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/31/2026 6:06 AM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/08/2026 4:34 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/06/2026 4:18 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:18 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:18 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:19 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:19 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/06/2026 4:19 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/02/2026 7:26 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
06/29/2026 6:07 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/29/2026 4:29 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:29 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:29 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:29 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:30 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/29/2026 4:30 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/26/2026 4:39 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
06/22/2026 5:59 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/22/2026 6:02 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
06/16/2026 5:01 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/15/2026 7:16 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
06/11/2026 7:13 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/10/2026 4:20 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/08/2026 5:13 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/03/2026 5:42 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2026 5:51 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2026 4:02 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:03 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:03 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:03 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:03 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/28/2026 4:04 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/26/2026 5:18 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2026 5:08 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2026 4:01 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Federal Reserve Reveals Disturbing New Plan To Control Your Money (Ad)

Docket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.tc pixel

Watch the video to learn how this plan could affect you
05/18/2026 4:01 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 4:02 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 4:02 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 4:02 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/18/2026 4:03 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/14/2026 4:23 PM
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
05/13/2026 3:06 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 6:56 PM
MPM BioVentures 2014, L.P. (1609492) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
05/12/2026 6:47 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 5:26 PM
Kolchinsky Peter (1384859) Reporting
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
Shah Rajeev M. (1619841) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 3:31 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:32 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:32 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:32 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:33 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/11/2026 3:33 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/07/2026 5:22 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 6:04 PM
MPM BioVentures 2014, L.P. (1609492) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
05/04/2026 5:00 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 3:52 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:52 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:51 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:51 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:51 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/01/2026 3:52 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 6:16 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2026 3:47 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:47 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:47 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:48 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:48 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/29/2026 3:48 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 3:59 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:00 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:00 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:00 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:01 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/27/2026 4:01 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/27/2026 6:07 AM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/27/2026 6:12 AM
Werewolf Therapeutics (1785530) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/24/2026 4:26 PM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/11/2026 2:46 PM
Longwood Fund III, L.P. (1640546) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13G/A
02/06/2026 3:41 PM
Werewolf Therapeutics (1785530) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/20/2026 3:07 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/16/2026 4:36 PM
MPM BioVentures 2014, L.P. (1609492) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
01/15/2026 4:22 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:09 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 4:12 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:58 PM
MPM Asset Management Investors BV2014 LLC (1609495) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:59 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Trump's about to unleash his Midterm Weapon (Ad)

Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.tc pixel

Read the full pre-midterm energy stock briefing now
01/06/2026 3:54 PM
MPM ONCOLOGY INNOVATIONS FUND LP (1719960) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:54 PM
MPM BioVentures 2014, L.P. (1609492) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:56 PM
UBS Oncology Impact Fund L.P. (1691428) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 3:57 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2026 4:32 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 5:59 PM
MPM BioVentures 2014, L.P. (1609492) Filed by
Werewolf Therapeutics (1785530) Subject
Form SCHEDULE 13D/A
12/29/2025 4:27 PM
EVNIN LUKE (1134657) Reporting
Werewolf Therapeutics (1785530) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 3:45 PM
MPM ASSET MANAGEMENT LLC (1263048) Reporting
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/29/2025 3:45 PM
MPM BioVentures 2014 (0) B
Werewolf Therapeutics (1785530) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)

Werewolf Therapeutics SEC Filings - Frequently Asked Questions

Werewolf Therapeutics (HOWL) has submitted 367+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Werewolf Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Werewolf Therapeutics's financial statements page.

The most recent filing was a Form S-4 submitted on September 22, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:HOWL are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/22/2026. New filings are added as they're published.
From Our Partners